Ahmad Tarhini: Important implications for drug development targeting the microbiome

Ahmad Tarhini, Director, Cutaneous Clinical and Translational Research at Moffitt Cancer Center and Research Institute, shared on LinkedIn:

“Our latest published article | The melanoma tumor microbiome and TME immunogenicity, response and resistance to immune checkpoint inhibitors | Important implications for drug development targeting the microbiome |

Proud of this collaboration with Daniel Spakowicz, Aik Choon Tan, Caroline Dravillas, Sam Coleman.”

‘The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors‘

Authors: Caroline E. Dravillas, Samuel S. Coleman, Rebecca Hoyd, Griffin Caryotakis, Louis Denko, Carlos H.F. Chan, Michelle L. Churchman, Nicholas Denko, Rebecca D. Dodd, Islam Eljilany, Sheetal Hardikar, Marium Husain, Alexandra P. Ikeguchi, Ning Jin, Qin Ma, Martin D. McCarter, Afaf E.G. Osman, Lary A. Robinson, Eric A. Singer, Gabriel Tinoco, Cornelia M. Ulrich, Yousef Zakharia, Daniel Spakowicz, Ahmad A. Tarhini, Aik Choon Tan.

Source: Ahmad Tarhini/LinkedIn